Tumor Biology

, Volume 34, Issue 2, pp 669–674 | Cite as

Prognostic significance of BMP7 as an oncogene in hepatocellular carcinoma

  • Wei Li
  • Hong-Xin Cai
  • Xu-Ming Ge
  • Kai Li
  • Wei-Dong Xu
  • Wei-Hong Shi
Research Article


This study aims to evaluate the association between BMP7 tissue expression and patient prognosis in hepatocellular carcinoma (HCC). The expression of BMP7 mRNA in HCC was characterized using real-time PCR and 30 pairs of fresh frozen HCC tissues and corresponding noncancerous tissues. BMP7 protein expression in HCC was confirmed using immunohistochemistry on a tissue microarray chip. Finally, BMP7 expression was correlated with conventional clinicopathological features of HCC and patient outcome. The expression of BMP7 mRNA and protein in HCC cells was much higher than in normal hepatic cells. Our results showed that the high expression of BMP7 in HCC was related to tumor size (p < 0.001), histological differentiation (p = 0.041), serum AFP (p = 0.007), and tumor stage (p < 0.001). Kaplan–Meier survival analysis showed that a high-expression level of BMP7 resulted in a significantly poor prognosis of HCC patients. Multivariate analysis revealed that BMP7 expression level was an independent prognostic parameter for the overall survival rate of HCC patients. These findings provide evidence that a high-expression level of BMP7 serves as a biomarker for poor prognosis for HCC. Thus, we speculate that BMP7 may be a potential target of antiangiogenic therapy for HCC.


BMP7 Hepatocellular carcinoma Biomarker Prognosis 


Conflict of interest



  1. 1.
    Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, TaylorRobinson SD. Hepatocellular carcinoma:current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol. 2009;3:353–67. doi: 10.1586/egh.09.35.PubMedCrossRefGoogle Scholar
  2. 2.
    Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int. 2008;7:237–57.PubMedGoogle Scholar
  3. 3.
    Koorey D. Hepatocellular carcinoma: prevention, detection and treatment in the real world. Intern Med J. 2007;37:513–5. doi: 10.1111/j.1445-5994.2007.01439.x.PubMedCrossRefGoogle Scholar
  4. 4.
    Pleguezuelo M, Marelli L, Misseri M, Germani G, Calvaruso V, Xiruochakis E, Pinelopi M, Burroughs AK. TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2008;8:1623–41. doi: 10.1586/14737140.8.10.1623.PubMedCrossRefGoogle Scholar
  5. 5.
    Patel SR, Dressler GR. BMP7 signaling in renal development and disease. Trends Mol Med. 2005;11:512–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Milan M. Sculpting a fly leg: BMP boundaries and cell death. Nat Cell Biol. 2007;9:17–8. doi: 10.1038/ncb0107-17.PubMedCrossRefGoogle Scholar
  7. 7.
    Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. Science. 2002;296:1646–7. doi: 10.1126/science.1071809.PubMedCrossRefGoogle Scholar
  8. 8.
    Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev. 2005;19:2783–810. doi: 10.1101/gad.1350705.PubMedCrossRefGoogle Scholar
  9. 9.
    Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, Schwaninger R, Henriquez NV, Ten Dijke P, Borovecki F, Markwalder R, Thalmann GN, Papapoulos SE, Pelger RC, Vukicevic S, Cecchini MG, Löwik CW, van der Pluijm G. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol. 2007;171:1047–57. doi: 10.2353/ajpath.2007.070168.PubMedCrossRefGoogle Scholar
  10. 10.
    Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, Kalluri R. Endothelial-tomesenchymal transition contributes to cardiac fibrosis. Nature. 2007;13:952–61. doi: 10.1038/nm1613.CrossRefGoogle Scholar
  11. 11.
    Alarmo EL, Rauta J, Kauraniemi P, Karhu R, Kuukasjärvi T, Kallioniemi A. Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer. Genes Chromosomes Cancer. 2006;45:411–9. doi: 10.1002/gcc.20307.PubMedCrossRefGoogle Scholar
  12. 12.
    Miyazaki H, Watabe T, Kitamura T, Miyazono K. BMP signals inhibit proliferation and in vivo tumor growth of androgeninsensitive prostate carcinoma cells. Oncogene. 2004;23:9326–35. doi: 10.1038/sj.onc.1208127.PubMedCrossRefGoogle Scholar
  13. 13.
    Beck SE, Jung BH, Del Rosario E, Gomez J, Carethers JM. BMP induced growth suppression in colon cancer cells is mediated by p. 21(WAF1) stabilization and modulated by RAS/ERK. Cell Signal. 2007;19:1465–72. doi: 10.1016/j.cellsig.2007.01.017.PubMedCrossRefGoogle Scholar
  14. 14.
    Motoyama K, Tanaka F, Kosaka Y, Mimori K, Uetake H, Inoue H, Sugihara K, Mori M. Clinical significance of BMP7 in human colorectal cancer. Ann Surg Oncol. 2008;15:1530–36. doi: 10.1245/s10434-007-9746-4.PubMedCrossRefGoogle Scholar
  15. 15.
    Huang J, Zhu H, Wang X, Tang Q, Huang H, Wu K, Zhu J, Feng Z, Shi G. The patterns and expression of KDR in normal tissues of human internal organs. J Mol Histol. 2011;42:597–603. doi: 10.1007/s10735-011-9355-1.PubMedCrossRefGoogle Scholar
  16. 16.
    Fang W, Li X, Jiang Q, Liu Z, Yang H, Wang S, Xie S, Liu Q, Liu T, Huang J, Xie W, Li Z, Zhao Y, Wang E, Marincola FM, Yao K. Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med. 2008;6:32. doi: 10.1186/1479-5876-6-32.PubMedCrossRefGoogle Scholar
  17. 17.
    Tu L, Liu Z, He X, He Y, Yang H, Jiang Q, Xie S, Xiao G, Li X, Yao K, Fang W. Over-expression of eukaryotic translation initiation factor 4 gamma 1 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma. Mol Cancer. 2010;9:78. doi: 10.1186/1476-4598-9-78.PubMedCrossRefGoogle Scholar
  18. 18.
    Liu Z, Li L, Yang Z, Luo W, Li X, Yang H, Yao K, Wu B, Fang W. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer. 2010;10:270. doi: 10.1186/1471-2407-10-270.PubMedCrossRefGoogle Scholar
  19. 19.
    Zhu X-D, Zhang J-B, Zhuang P-Y, Zhu H-G, Zhang W, Xiong Y-Q, Wei-Zhong Wu L, Wang Z-YT, Sun H-C. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008;26:2707–16. doi: 10.1200/JCO.2007.15.6521.PubMedCrossRefGoogle Scholar
  20. 20.
    Kelly K, Crowley J, Bunn Jr PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210–8.PubMedGoogle Scholar
  21. 21.
    Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol. 2004;5:341–53.PubMedCrossRefGoogle Scholar
  22. 22.
    Peng SY, Lai PL, Chu JS, Lee PH, Tsung PT, Chen DS, Hsu HC. Expression and hypomethylation of alpha-fetoprotein gene in unicentric and multicentric human hepatocellular carcinomas. Hepatology. 1993;17:35–41.PubMedCrossRefGoogle Scholar
  23. 23.
    Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY. β-catenin mutations are associated with a subset of low stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol. 2000;157:763–70.PubMedCrossRefGoogle Scholar
  24. 24.
    Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS, Chambers AF. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer. 1998;79:502–8. doi: 10.1002/(SICI)1097-0215(19981023.PubMedCrossRefGoogle Scholar
  25. 25.
    Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, Tahara E. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer. 1998;79:127–32. doi: 10.1002/(SICI)1097-0215(19980417.PubMedCrossRefGoogle Scholar
  26. 26.
    Hwang YH, Choi JY, Kim S, Chung ES, Kim T, Koh SS, Lee B, Bae SH, Kim J, Park YM. Over-expression of c-raf-1proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res. 2004;29:113–21.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • Wei Li
    • 1
  • Hong-Xin Cai
    • 2
  • Xu-Ming Ge
    • 1
  • Kai Li
    • 1
  • Wei-Dong Xu
    • 1
  • Wei-Hong Shi
    • 2
  1. 1.Department of Liver and Biliary SurgeryThe First People’s Hospital of LianyungangLianyungangChina
  2. 2.Department of Medical TechnologyYancheng Health Vocational and Technical CollegeYanchengChina

Personalised recommendations